National Priority List of Pediatric Drugs

The National Priority List of Pediatric Drugs is a list of medicinal ingredients that the Pediatric External Reference Group has identified to address areas of unmet pediatric needs in Canada.

The medicinal ingredients on the draft list fall under one of the following categories:

The list includes line listings of ingredients and any applicable qualifiers. Qualifiers for medicinal ingredients that are not on the Canadian market are indicated by n/a (not applicable) in the table. A relevant qualifier is provided where the specific route of administration is relevant or where the medicinal ingredient exists in multiple formats and the identified need is particular.

Child-friendly drug formats are formulations that are more easily adjustable for pediatric dosing requirements. They often taste better than adult drugs and are easier to give to children. Some examples of child-friendly oral route drug formats include oral liquids, oral dispersible tablets and granules for suspension.

Table 1: List of medicinal ingredients
Medicinal ingredient contained in drug Qualifier
Drugs not currently available in Canada
Albendazole n/a
Chenodeoxycholic acid (CDCA) n/a
Fish oil triglycerides Emulsion, intravenous route, when recommended for treating parenteral nutrition-associated cholestasis in pediatric patients
Glucarpidase n/a
Griseofulvin n/a
Ibuprofen lysine Injection, for intravenous use
Sargramostim n/a
Sodium benzoate, Sodium phenylacetate In combination
Sulfadiazine n/a
Sulthiame n/a
Zonisamide n/a
On-market drugs needing child-friendly formats only
Cyclopentolate-Phenylephrine In combination
Atomoxetine Oral route
Baclofen Oral route
Calcitriol Oral route
Clobazam Oral route
Dexamethasone Oral route
Diazoxide Oral route
Mercaptopurine Oral route
Prednisolone Oral route, high concentration
Rifampin Intravenous route
Tacrolimus Oral route
On-market drugs needing pediatric indications only
Aripiprazole When recommended for treating irritability associated with autism spectrum disorder or for treating Tourette's disorder
Brentuximab vedotin When recommended for treating high-risk classical Hodgkin lymphoma
Fluoxetine Pediatric indication
Rituximab Pediatric indication
On-market drugs needing pediatric indications and child-friendly formats
Domperidone Oral route, pediatric indication
Escitalopram Oral route, pediatric indication
Hydroxocobalamin Intramuscular route, when recommended for treating conditions leading to Vitamin B 12 deficiency
Hydroxyurea Oral route, when recommended for treating sickle cell disease
Midazolam Nasal route, when recommended for treating acute seizure activity
Raltegravir Oral route, extension of pediatric indication
Sildenafil Oral route, pediatric indication
Sotalol Oral route, pediatric indication
Spironolactone Oral route, pediatric indication
Tofacitinib Oral route, extension of pediatric indication
Ursodiol Oral route, pediatric indication

Page details

2025-09-17